CompletedPhase 3NCT01730937
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Radiation Therapy Oncology Group
- Principal Investigator
- Laura DawsonRadiation Therapy Oncology Group
- Intervention
- Sorafenib(drug)
- Enrollment
- 193 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2025
Study locations (30)
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCSF Medical Center-Mount Zion, San Francisco, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- Saint Vincent's Medical Center, Bridgeport, Connecticut, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- Queen's Medical Center, Honolulu, Hawaii, United States
- Northwestern University, Chicago, Illinois, United States
- University of Illinois, Chicago, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Iowa Methodist Medical Center, Des Moines, Iowa, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01730937 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital